Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 13/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KLK1 | P06870 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PRKX | P51817 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092961 | 0.90 | MMP13 (0.63) | MMP13ATMROCK2CYP3A4CYP2D6 | |
| SCHEMBL14485367 | 0.82 | KLKB1 (0.72) | KLKB1KLK1 | |
| SCHEMBL14486028 | 0.82 | KLKB1 (0.78) | KLKB1KLK1 | |
| SCHEMBL13940425 | 0.82 | MMP13 (0.90) | MMP13ROCK2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21669910 | 0.81 | KLKB1 (0.88) | KLKB1KLK1 | |
| SCHEMBL14486005 | 0.81 | KLKB1 (0.88) | KLKB1KLK1 | |
| SCHEMBL14486026 | 0.79 | KLKB1 (0.88) | KLKB1KLK1 | |
| SCHEMBL5334260 | 0.78 | MMP13 (0.85) | MMP13ROCK2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14485480 | 0.77 | KLKB1 (0.76) | KLKB1CTSLCTSSKLK1 | |
| SCHEMBL20873686 | 0.76 | KLKB1 (0.76) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005419-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1859278-A1 | METHOD FOR THE SCREENING OF COMPOUNDS THAT MODULATE THE INTERACTION BETWEEN MRNA AND PROTEINS AND COMPOUNDS OBTAINABLE THEREBY | Novartis AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094688-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005419-A1 | Organic Compounds | ELAVL1, RBM3, RRBP1 | MMP13 4726/4885KLKB1 4436/4885CTSL 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.